These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7724751)

  • 1. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
    Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
    Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
    Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
    Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
    Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
    Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.
    Zimny M; Bares R; Fass J; Adam G; Cremerius U; Dohmen B; Klever P; Sabri O; Schumpelick V; Buell U
    Eur J Nucl Med; 1997 Jun; 24(6):678-82. PubMed ID: 9169578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
    Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
    World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions.
    Papós M; Takács T; Trón L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Pávics L
    Clin Nucl Med; 2002 Mar; 27(3):197-201. PubMed ID: 11852308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET evaluation of indeterminate pancreatic masses.
    Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
    J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.
    Kato T; Fukatsu H; Ito K; Tadokoro M; Ota T; Ikeda M; Isomura T; Ito S; Nishino M; Ishigaki T
    Eur J Nucl Med; 1995 Jan; 22(1):32-9. PubMed ID: 7698152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
    Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC
    AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of pancreatic carcinoma: role of FDG PET.
    Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
    AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results.
    Bares R; Klever P; Hellwig D; Hauptmann S; Fass J; Hambuechen U; Zopp L; Mueller B; Buell U; Schumpelick V
    Nucl Med Commun; 1993 Jul; 14(7):596-601. PubMed ID: 8355920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma.
    Nakata B; Chung YS; Nishimura S; Nishihara T; Sakurai Y; Sawada T; Okamura T; Kawabe J; Ochi H; Sowa M
    Cancer; 1997 Feb; 79(4):695-9. PubMed ID: 9024707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.
    Sperti C; Pasquali C; Chierichetti F; Liessi G; Ferlin G; Pedrazzoli S
    Ann Surg; 2001 Nov; 234(5):675-80. PubMed ID: 11685032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
    Voth M; Opfermann T; Gottschild D
    Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.